以下文章来源于投资界 ，作者吴琼 投资界 . 清科控股旗下创业与投资资讯平台 最新发布的《2025胡润百富榜》显示，钟慧娟以1410亿元的财富取代宗馥莉，成为新晋女首富。 钟慧娟，医药圈并不陌生——她是港股上市公司翰森制药创始人、董事会主席、首席执行官兼执行董事。 早年毕业于化学专业，钟慧娟从教师岗位转战医药圈，最终坐拥一家上市公司。 而她的丈夫孙飘扬，同样大名鼎鼎，如今管理着市值5000亿港元的恒瑞医药。夫妻两人分别做出了一家千 亿上市公司，即便放眼整个中国创投圈也是绝无仅有。 钟慧娟身家大涨背后，是她所执掌的翰森制药今年市值从900亿一路上涨到2000多亿港元，成为生物医药集 体爆发的一抹缩影。 市值2000亿 她成为新晋女首富 一切始于三十年前。 钟慧娟是江苏连云港人，1982年从江苏师范大学化学专业本科毕业后，成为连云港延安中学的一名化学老 师。后来钟慧娟从人民教师转型创业，进军医药圈，这离不开她的丈夫孙飘扬。 1995年，孙飘扬和一名香港投资人组建一家新企业——豪森药业，也就是翰森制药的前身。但当时孙飘扬 已经是连云港制药厂厂长，抽不开身。于是，钟慧娟便辞掉老师的工作，加入翰森制药，承担起管理公司 ...

这位曾经的化学教师"白手起家"财富攀升，背后是其所执掌的翰森制药市值在年内一路飙升——从约900亿港元到如今突破2000亿港元，令业界瞩目。 钟慧娟在医药行业为人所熟知，还因其与丈夫孙飘扬分别掌控着翰森制药和恒瑞医药这两家上市药企，构成"最牛夫妻档"。其财富增长与翰森制药向创新 药的战略转型，以及创新药领域的整体爆发密不可分。 来源：凤凰网财经《公司研究院》 然而，这家药企财富积累的道路上，曾有着挥之不去的合规阴影。其财务报告显示，公司的销售及分销开支已持续七年维持在30亿元以上的高位。其旗下 子公司还曾因不正当竞争行为，被罚款2554万元。这些情况引发了市场对其高额营销费用背后商业模式的关注。 10月28日，胡润研究院的一纸榜单，将翰森制药董事局主席钟慧娟与其女孙远以1410亿元财富推上了中国女首富之位，一举取代了此前备受关注的娃哈哈 集团宗馥莉。 如今，这位新晋女首富与其掌舵的医药帝国，正同时面对着创新药成果与商业合规性的双重审视。 01 迎上创新药爆发 医药圈从来不缺故事，但像钟慧娟这样从化学老师"白手起家"到中国女首富的剧本，即便在最跌宕的商战小说里也难得一见。 这位翰森制药的掌舵人携女儿孙远以141 ...

以下文章来源于投资界 ，作者吴琼 投资界 . 清科控股旗下创业与投资资讯平台 ，， 本文转载自投资界 值班编辑 ｜ 江江 视觉 | 顾芗 最新发布的《2025胡润百富榜》显示，钟慧娟以1410亿元的财富取代宗馥莉，成为新晋女首富。 钟慧娟，医药圈并不陌生——她是港股上市公司翰森制药创始人、董事会主席、首席执行官兼执行董 事。早年毕业于化学专业，钟慧娟从教师岗位转战医药圈，最终坐拥一家上市公司。 而她的丈夫孙飘扬，同样大名鼎鼎，如今管理着市值5000亿港元的恒瑞医药。夫妻两人分别做出了一家 千亿上市公司，即便放眼整个中国创投圈也是绝无仅有。 钟慧娟身家大涨背后，是她所执掌的翰森制药今年市值从900亿一路上涨到2000多亿港元，成为生物医 药集体爆发的一抹缩影。 市值2000亿 她成为新晋女首富 一切始于三十年前。 钟慧娟是江苏连云港人，1982年从江苏师范大学化学专业本科毕业后，成为连云港延安中学的一名化学 老师。后来钟慧娟从人民教师转型创业，进军医药圈，这离不开她的丈夫孙飘扬。 1995年，孙飘扬和一名香港投资人组建一家新企业——豪森药业，也就是翰森制药的前身。但当时孙飘 扬已经是连云港制药厂厂长，抽不开身。 ...

| | | | 《2025胡润女企业家榜》 前十名 | | | | | --- | --- | --- | --- | --- | --- | --- | | | 姓名 | 财富(亿元人民币) | 财富变化 = | 公司 | 主业 | 居住地 - 年龄 | | 11 | 钟慧娟、孙远母女 | HURUN IN CHIN 410 | 83% | 駒森 | 医药 | 连云港 64.38 | | 21 | 周群で | 湖润又正100 | 75% | 蓝思科技 | 消费电子 | 长沙 રેર | | 31 | 宗觀莉 | 875 | 8% | 娃哈哈 | 饮料 | 43 杭州 | | 41 | 王来春 | 822 | 38% | 立讯精密 | 式 消费电子 | 深圳 ਟੋਲ | | 214- | 日 - 三 / 3 月 / | 830 | 25% | 新鸿基 | 房地产P | 香港 96 | | 6* | ■ 曾芳勤 | રતેર | 83% | 领益智造 | 消费电子 | 深圳 60 | | 7* | 张红霞 | 600 | 60% | 魏桥创业 | 铝业、纺织 | 漫 54 | | 8* | 张掖红 | ર્ ર ...

Core Viewpoint - The article highlights the rise of Zhong Huijuan as the new richest woman in China, with a wealth of 141 billion yuan, primarily due to the significant increase in the market value of Hansoh Pharmaceutical, which surged from approximately 90 billion to over 200 billion HKD this year, reflecting the booming biopharmaceutical sector [4][7]. Company Overview - Zhong Huijuan is the founder, chairman, and CEO of Hansoh Pharmaceutical, which has transitioned from a generic drug company to an innovative drug enterprise focusing on major disease treatments such as oncology and autoimmune diseases [6][7]. - The company went public on the Hong Kong Stock Exchange in June 2019, marking a significant milestone in its growth trajectory [6]. Financial Performance - Hansoh Pharmaceutical's market value increased dramatically this year, with a year-to-date stock price increase of over 100%, contributing to Zhong Huijuan's wealth growth of over 60 billion yuan compared to the previous year [7]. - The company recently secured a major deal with Roche for a CDH17-targeted antibody-drug conjugate, which includes an upfront payment of 80 million USD and potential milestone payments totaling up to 1.45 billion USD, indicating a lucrative revenue stream from this single drug [7]. Industry Context - The biopharmaceutical sector in China is experiencing a significant boom, with many companies in the innovative drug space seeing substantial increases in their valuations and stock prices [12][14]. - The total value of business development (BD) transactions in China's innovative drug sector reached 63.55 billion USD in the first half of the year, surpassing the total for the entire year of 2024, highlighting the sector's rapid growth and investment interest [14][15]. - The article notes a trend of increasing wealth among pharmaceutical entrepreneurs, with several individuals in the industry experiencing significant financial gains due to the favorable market conditions [12][14]. Market Dynamics - The article mentions a recent adjustment period for the innovative drug sector, with some leading companies experiencing notable stock price corrections, indicating potential volatility in the market despite the overall growth [15].

有华人的地方，就有最华人。 关注华人商业领袖、创业者及商业案例； 洞察科技制造、品牌出海、产 业革新等。 "2022中国正能量网络精品"获得者。 以下文章来源于最华人 ，作者华人作者团 最华人 . 来源丨最华人（ID： wcweekly ） 作者丨 荠麦青青 图源丨Midjourney 在当今世界上，财富是另一种"江山"，它涨落无定，却见证着时代大潮的汹涌澎湃。伴随着诸多财富 神话的诞生，我们看到了在风云际会与壮怀激烈之下，一切能够抵达的巅峰。 最新发布的《2025胡润百富榜》显示，钟慧娟、孙远母女以1410亿元的财富取代宗馥莉，成为新晋 女首富。 与高居榜首的位次相比，更令人惊叹的是她的财富涨幅——在2024年的榜单上，钟慧娟还只有530亿，仅 过了一年，她的财富却已超越千亿，这意味着崛起速度惊人的"医药一姐"日赚3亿。 在医药界，她创造的奇迹成为了一个跨界者值得探究的范本。 钟慧娟 改变"赛道" 钟慧娟是中国1977年恢复高考后首批被录取的大学生，当时百废待兴的神州大地上涌动着知识改变命运 的热潮，但那个年代大学录取比例极低，当年共有573万考生，最终被录取的只有27万，录取率仅为 4.7%。 钟慧娟就读 ...

以下文章来源于投资界 ，作者吴琼 投资界 . 清科控股旗下创业与投资资讯平台 乘上东风。 作者：吴琼 来源：投资界 最新发布的《2025胡润百富榜》显示，钟慧娟以1410亿元的财富取代宗馥莉，成为新晋女首 富。 钟慧娟，医药圈并不陌生——她是港股上市公司翰森制药创始人、董事会主席、首席执行官兼 执行董事。早年毕业于化学专业，钟慧娟从教师岗位转战医药圈，最终坐拥一家上市公司。 而她的丈夫孙飘扬，同样大名鼎鼎，如今管理着市值5000亿港元的恒瑞医药。夫妻两人分别 做出了一家千亿上市公司，即便放眼整个中国创投圈也是绝无仅有。 钟慧娟身家大涨背后，是她所执掌的翰森制药今年市值从900亿一路上涨到2000多亿港元，成 为生物医药集体爆发的一抹缩影。 这里插播一条课程资讯： 报名 「 黑马·日本游学 」 ， 11月30日-12月5日， 我们将带着黑马的同学，一起去日本学 习： 日本品牌穿越周期背后的经营密码。 共同拆解 日本在低增长、少子化、高龄化背后，怎样孕育出如此多行业的领军企业？ 包括大家熟悉的 三得利、711、花王、FANCL、神户物产、WORKMAN 等知名企业。 6天5晚，让我们 共同预见未来20年中国消费市 ...

Core Insights - The article highlights the remarkable transformation of Zhong Huijuan from a chemistry teacher to the wealthiest woman in China, with a net worth of 141 billion yuan, surpassing the previous titleholder, Zong Fuli [2][3]. Company Development - Zhong Huijuan co-founded Hansoh Pharmaceutical in 1995 after leaving her stable teaching job, marking a significant career shift [4]. - Initially a small pharmaceutical company, Hansoh Pharmaceutical capitalized on the growth opportunities in China's pharmaceutical industry [6]. - The company's first major product, an antibiotic named "Meifeng," was launched in 1997, generating 30 million yuan in revenue that year, validating Zhong's business acumen [7]. Market Performance - Hansoh Pharmaceutical went public on the Hong Kong Stock Exchange in June 2019, which was a pivotal moment for the company, providing substantial capital for growth [8]. - The company's market capitalization surged from approximately 90 billion HKD to over 200 billion HKD within a year, significantly boosting Zhong's wealth [8]. - For the year 2024, Hansoh Pharmaceutical reported revenues of 13.483 billion yuan, a year-on-year increase of 12.3%, and a net profit of 4.558 billion yuan, up 10% from the previous year [8]. Industry Context - Zhong Huijuan and her husband, Sun Piaoyang, lead two major pharmaceutical companies, with their combined wealth showcasing the potential of the pharmaceutical sector in China [9]. - Their independent management styles and strategic visions highlight the diverse approaches within the industry [9]. Inspirational Narrative - Zhong Huijuan's journey exemplifies courage, transformation, and professionalism, serving as a role model for women in business [10][11]. - Her story illustrates that background does not dictate success, and with determination and intelligence, extraordinary achievements are possible [11].

Core Insights - The article highlights the rise of Zhong Huijuan as the new richest woman in China, with a wealth of 1.4 billion yuan, surpassing Zong Fuli [3][7] - Zhong Huijuan is the founder and CEO of Hansoh Pharmaceutical, which has seen its market value increase from approximately 90 billion to over 200 billion HKD this year, reflecting the booming biopharmaceutical sector [4][7] Company Overview - Hansoh Pharmaceutical started as a generic drug manufacturer and has transitioned into an innovative drug company focusing on major disease treatments such as oncology and autoimmune diseases [6][7] - The company went public on the Hong Kong Stock Exchange in June 2019, marking a significant milestone in its growth trajectory [6] Market Performance - Hansoh Pharmaceutical's stock price has surged over 100% this year, contributing significantly to Zhong Huijuan's wealth increase of over 600 billion yuan [7][12] - The company recently secured a major deal with Roche for a drug, which includes an upfront payment of 8 million USD and potential milestone payments totaling up to 1.45 billion USD, indicating strong revenue potential [7] Industry Trends - The biopharmaceutical sector in China is experiencing a wealth boom, with several entrepreneurs in the innovative drug space seeing significant increases in their fortunes [11][12] - The total value of business development (BD) transactions in China's innovative drug sector reached 63.55 billion USD in the first half of the year, surpassing the total for the entire previous year [12][13] - A surge in IPOs and listings in the biopharmaceutical sector is noted, with 14 companies announcing plans to go public in Hong Kong in September alone [13]

Core Insights - The article highlights that only 13 women globally have become billionaires by founding healthcare companies, with 7 of them from China, indicating a significant presence of Chinese female entrepreneurs in the healthcare sector [1][3]. Industry Overview - The Chinese biopharmaceutical industry is experiencing a transformative phase, referred to as the "DeepSeek moment," as it evolves from being a "generic drug powerhouse" to a competitive force against Western innovation in pharmaceuticals [2]. - In 2024, over 1,250 new drug candidates are expected to enter the research and development phase in China, surpassing the European Union and nearly matching the United States' 1,440 candidates [2]. - Nearly one-third of the drug candidates licensed by large pharmaceutical companies in 2024 are from Chinese firms, a significant increase from zero in 2019 [3]. Company Highlights - **Hansoh Pharmaceutical Group**: Founded by Zhong Huijuan, the company reported a total revenue of approximately 12.26 billion yuan in 2024, with a year-on-year growth of about 21.3% [7]. - **Aimeike**: Founded by Jian Jun, the company specializes in hyaluronic acid production and was listed on the A-share market in 2020, achieving a market value exceeding 170 billion yuan [10]. - **Qizheng Tibetan Medicine**: Founded by Lei Jufang, the company generated sales revenue of 1.655 billion yuan in 2024, with a year-on-year growth of 16.31% [14]. - **Haisco Pharmaceutical Group**: Co-founded by Fan Xiulian, the company reported a revenue of 3.721 billion yuan in 2024, with a year-on-year increase of 10.92% [17]. - **Teva Biopharmaceuticals**: Founded by Yang Ying, the company has shown rapid growth, with revenues increasing from 1.527 billion yuan in 2022 to 2.817 billion yuan in 2024 [18]. - **Kangfang Biopharmaceutical**: Founded by Xia Yu, the company has developed several innovative drugs and is recognized for its leading position in the biopharmaceutical sector [23]. - **Xinlitai**: Co-founded by Liao Qingqing, the company has shifted focus to self-research and development, achieving a revenue of 4.012 billion yuan in 2024, with a year-on-year growth of 19.22% [26].